| CASE REPORT |
|
| Year : 2023 | Volume
: 3
| Issue : 2 | Page : 357-359 |
|
|
Migration of dexamethasone implant (OZURDEX®) into the anterior chamber in a pseudophakic eye with an intact capsular bag
Bristi Majumdar1, Ahana Sen1, Nikita Goel1, Zubin D'Souza1, Sanatombi Thounaojam1, Surabhi Chattree1, Mona Bhargava2, Jay Shree3, Kumar Saurabh4, Rupak Roy1
1 Department of Vitreo Retina, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India
2 Department of Cornea, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India
3 Department of Glaucoma, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India
4 Departement of Vitreo Retina, Nethralayam Superspeciality Eye Hospital, Kolkata, West Bengal, India
Correspondence Address:
Rupak Roy
Aditya Birla Sankara Nethralaya, 147, Mukundapur, E.M.Bypass, Kolkata . 700 099, West Bengal
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/IJO.IJO_3127_22
|
|
|
Ozurdex® (Allergan, Inc., Irvine, CA, USA) is an intravitreal sustained-release drug delivery system containing dexamethasone, mainly used for the treatment of macular edema in diabetes, retinal vein occlusions or treatment of non-infectious posterior uveitis, as approved by the US FDA. It can be implanted into the vitreous cavity via the pars plana route. Migration of this implant into the anterior chamber may occur in cases of aphakia, pseudophakia with defective lens capsule, zonular dehiscence, iatrogenic, or as in pseudoexfoliation syndrome. We report a case of a pseudophakic patient with intact posterior capsule and no significant history suggesting a zonular weakness, who presented with diminution of vision due to anterior migration of the dexamethasone implant and its effects on the cornea. Measurements of specular microscopy provide useful information which may aid in management pre- and post-removal of migrated implant.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
